As a clinical trial sponsor, being able to measure research programs with pinpoint accuracy is a valuable proposition.
As a clinical trial sponsor, being able to measure research programs with pinpoint accuracy is a valuable proposition. That's precisely what DAC Patient Recruitment Services (DAC), an Imperial company and a leader in clinical trial patient recruitment and retention, offers through its proprietary DACTracks™ technology.
"Evaluating real-time program data is essential in analyzing return on investment," said DAC Vice President of Operations Melynda Geurts. "That is why DAC created DACTracks. This active, online reporting system keeps valuable program data at our clients' fingertips."
Sponsors will enjoy 24-hour access to reports on their research sites' screenings, referrals, randomizations (projected and actual), enrollment, attrition, and more. Both site-specific and global data are available. Impact graphs map recruitment trends following the launch of specific initiatives, and charts display the number of aggregate and site-specific referrals color-coded by source. The retention page features the total number of active and non-active subjects in the study and a summary of discontinued subjects, including reasons for discontinuation.
DACTracks also provides comprehensive statistics on study website performance, including unique site visitors, page views, online pre-qualification, and web traffic sources. Regarding the latter, users will be able to discern at the click of a mouse whether web traffic originated from search engines, referring sites or direct traffic to the study website URL.
For more information about DACTracks, and to sign up for a free demonstration, visit www.imperialcrs.com/dac/dactracks or write to [email protected]
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.